Daewoong

003090 · KOSPI · Health Care · SMALL CAP

Revenue up 22.8% in FY2025.

Daewoong reported a subsidiary's separate results for FY2025: revenue of US$7.64M (+22.8% year on year), an operating loss of US$160K and net income of US$1.1M (+121.7% year on year).

Earnings(Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary))· FILED 2026-03-09· RCEPT 20260309801112

US$7.64MRevenue
+22.8%Revenue vs a year earlier
−US$160KOperating profit

Converted at 1 USD ≈ ₩1,483.89 (filing-date rate, 2026-03-09 close)

What happened

Daewoong reported a subsidiary's separate results for FY2025: revenue of US$7.64M (+22.8% year on year), an operating loss of US$160K and net income of US$1.1M (+121.7% year on year).

Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.

RevenueUS$7.64M
Revenue vs a year earlier+22.8%
Operating profit−US$160K
Net incomeUS$1.1M
PeriodFY2025 (separate)
Filed2026-03-09, Change of 30% or more in revenue or profit/loss structure (15% for large companies) (subsidiary)
SourceDART rcept 20260309801112 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-03-09 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.